ISSUE 1382
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
An intranasal formulation of ketorolac tromethamine (Sprix – Lutipold) has been approved by the FDA for short-term (up to 5 days) treatment of moderate to moderately severe pain in adults. It is the first nonsteroidal anti-inflammatory drug (NSAID) to become available in an intranasal formulation. Ketorolac tromethamine is also available in oral, ophthalmic and injectable formulations.1
NSAIDS FOR PAIN — Use of an NSAID in addition to an opioid analgesic for management of postoperative pain has been shown to improve pain control and reduce opioid use, but administration of an oral NSAID may not be possible immediately after surgery. Intravenous or intramuscular (IM) ketorolac has been shown to be comparable in analgesic efficacy to moderate doses of morphine, but can cause severe gastrointestinal toxicity and is not recommended for more than 5
... more1. Drugs for pain. Treat Guidel Med Lett 2010; 8:25.
3. N Singla et al. Intranasal ketorolac for acute postoperative pain. Curr Med Res Opin 2010; 26:1915.
4. Wholesale acquisition cost (WAC), which represents the manufacturer’s published catalog or list price for a drug product to wholesalers and may not represent actual transactional prices. Source: reprinted with permission by First Databank, Inc. All rights reserved. © 2012. http://www.firstdatabank.com/Support/drug-pricing-policy.aspx. Accessed January 9, 2012.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1382d
Electronic, downloadable article - $45
